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PharmacokineticCurrent drug eluting stent (DES) technology is not optimized with regard to the pharmacokinetics of drug de-
livery. A novel, absorbable-coating sirolimus-eluting stent (AC-SES) was evaluated for its capacity to deliver
drug more evenly within the intimal area rather than concentrating drug around the stent struts and for its
ability to match coating erosion with drug release. The coating consisted of absorbable poly-lactide-co-
glycolic acid (PLGA) and crystalline sirolimus deposited by a dry-powder electrostatic process. The AC-SES
demonstrated enhanced drug stability under simulated use conditions and consistent drug delivery balanced
with coating erosion in a porcine coronary implant model. The initial drug burst was eliminated and drug re-
lease was sustained after implantation. The coating was absorbed within 90 days.
Following implantation into porcine coronary arteries the AC-SES coating is distributed in the surrounding
intimal tissue over the course of several weeks. Computational modeling of drug delivery characteristics
demonstrates how distributed coating optimizes the load of drug immediately around each stent strut and
extends drug delivery between stent struts. The result was a highly efﬁcient arterial uptake of drug with su-
perior performance to a clinical bare metal stent (BMS). Neointimal thickness (0.17±0.07 mm vs. 0.28±
0.11 mm) and area percent stenosis (22±9% vs. 35±12%) were signiﬁcantly reduced (pb0.05) by the
AC-SES compared to the BMS 30 days after stent implantation in an overlap conﬁguration in porcine coro-
nary arteries. Inﬂammation was signiﬁcantly reduced in the AC-SES compared to the BMS at both 30 and
90 days after implantation.
Biocompatible, rapidly absorbable stent coatings enable the matching of drug release with coating erosion
and provide for the controlled migration of coating material into tissue to reduce vicissitudes in drug tissue
levels, optimizing efﬁcacy and reducing potential toxicity.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Coronary arterial drug-eluting stent (DES) signiﬁcantly improved
outcomes and reduced the need for additional interventions. Millions
have beneﬁted from this technology and the knowledge gained from
extensive use of these products has provided insights into aspects of
the technology critical to therapeutic effectiveness. Essential attri-
butes include use of an underlying balloon delivery catheter opti-
mized for ﬂexibility and placement accuracy; a stent platform that
minimizes strut thickness and a drug-eluting coating that optimizese), +1 203 300 4277 (mobile).
. Carlyle),
(A.R. Tzafriri),
), pmarkham@cbset.org
@mit.edu (E.R. Edelman).
rights reserved.local antiproliferative therapy with coating compositions that mini-
mize any inﬂammatory response.
Several lessons are emerging as dominant in the DES era – in par-
ticular the role of stent design and geometry, and the material and
coating characteristics. Thinner struts, for example, reduce intimal
hyperplasia and thrombotic potential, improving clinical outcomes
[1,2]. Less clear is how to formulate the coating to optimize drug de-
livery and device biocompatibility.
Restenosis is most likely in the months immediately following
stent placement [3]. Injury to the vessel wall is a triggering event
and a subsequent inﬂammatory response will continue to encourage
neointimal hyperplasia and vascular restenosis. Any component of
the DES that exacerbates the inﬂammatory response or delays healing
of the vessel will prolong the risk of adverse events such as late stent
thrombosis. Although most polymer coatings have some inﬂammato-
ry potential [4], the coating is needed to secure the drug to the device
during delivery and to control release of the drug after implantation.
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therapeutic drug and a much longer (usually permanent) presence
of the potentially inﬂammatory polymer coating. Absorbable polymer
coatings that fully degrade and leave a bare metal stent provide the
opportunity for more optimum long-term biocompatibility [5].
Drug release from current DES coatings is controlled by the rates
of water imbibition into the polymer coating, subsequent dissolution
of the drug and diffusion of soluble drug out of the polymer matrix
[6]. Release is therefore exponential with an initial burst phase
corresponding to rapid dissolution of surface drug [7]. This burst re-
lease may present the artery with more drug than it can retain
resulting in measurable systemic drug levels [8]. The ensuing expo-
nential decay of drug delivery means that drug release is constantly
declining such that the interval during which optimal drug dosing is
achieved may be very limited.
A common concern is that stent-based drug delivery patterns tend
to track the structure of the stent scaffold [9–11], and that this might
result in suboptimal dosing between the struts and excessive dosing
adjacent to stent struts. We used in vivo and computational models
to determine whether a DES product could reduce the peaks and val-
leys in drug concentration by creating a formulation whose coating
could be deployed away from the strut to more uniformly distribute
drug through the vessel wall. We further sought to determine if a
coating material deployed in this manner could be made to absorb
rapidly relative to the duration of drug elution without eliciting a sig-
niﬁcant inﬂammatory response.
2. Methods
2.1. AC-SES
An absorbable coating-sirolimus-eluting stent (AC-SES: MiStent®
Sirolimus Eluting Absorbable Polymer Coronary Stent System, Micell
Technologies, Inc., Durham, NC) was based on a cobalt-chromium
stent platform (GENIUS® Magic, Eurocor GmbH, Bonn Germany)
[12] The stent has thin 0.0025 inch struts. The coating consists of
sirolimus combined with an absorbable polymer, poly(lactide-co-
glycolic acid) (PLGA). Unique to this DES is the combination of the
absorbable polymer and drug components using a dry powder elec-
trostatic coating process. This product is not currently approved for
commercial distribution.
2.2. Stent coating
A detailed description of the stent coating procedure can be found
in the supplemental materials and is outlined in Fig. 2.
2.3. SEM imaging
Samples were sputter coated with platinum for 1.5 min to achieve
a coating of approximately 15 nm. Imaging was performed at Evan
Analytical Laboratories (Raleigh, NC) on a Hitachi S-4700 Field Emis-
sion scanning electron microscope. Images were acquired ranging
from 35× to 5000× magniﬁcation.
2.4. Drug stability measurements
Drug stability assessment under simulated use conditions was
performed at Euroﬁns Medinet, Inc. (Aurora, CO). For these experi-
ments drug stability within the AC-SES containing crystalline sirolimus
was compared to sirolimus stability in a standard, commercially avail-
able DES product that consists of amorphous drug in a permanent poly-
mer [7]. A total of six Cypher® DES controls (Cordis, Miami Lakes, FL)
and twelve AC-SES were used for the stability assessment. The coating
was dissolved and extracted from three controls and six AC-SES test
articles by addition of 2 ml acetone:methanol (50:50) at baseline forreference to incubated stents. The remaining stents were incubated
for 14 days in serum supplemented cell culture media at 37 °C. At the
end of this period, the stentswere removed and their coatings extracted
as described above. Extracted samples were stored at−80 °C such that
quantiﬁcation was performed simultaneously on all samples. A fully
validated method employing HPLC linked to tandem mass spectrome-
try (HPLC-MS/MS) was used for analysis of sirolimus and degradants.
The analysis was performed using an API 4000 Triple Quad Mass Spec-
trometer (AB Sciex Instruments) paired to aWaters AcquityHPLC system.
Data were captured and analyzed within the Analyst 4.2.1 software
package. Sirolimus content was analyzed to quantify relative amount of
parent drug and primary degradants.
2.5. Flow loop studies
An in vitro ﬂow loop consisting of a 60 cm long, 3.35 mm diameter
Silastic® tube was used to create controllable, vessel-like ﬂow condi-
tions as determined by velocity, pressure and wall shear stress. Indi-
vidual AC-SES were deployed inside the ﬂow loop and expanded at
8 bar to ensure complete apposition to the tubing wall. The system
was ﬁlled with a 0.01 M PBS/7.5% BSA solution at 37 °C. The loops
were loaded into the ﬂow system and exposed to controlled coronary
artery-like ﬂow (pulsatile, 15 dyn/cm2) at 37 °C for 4 h, 1, 3, 7 and
14 days. Immediately following the speciﬁed run time, the loops
were removed, emptied, ﬂushed with PBS to remove non-adherent
debris and stored for subsequent imaging. AC-SES samples were
kept in the tube and immersed in PBS, then photographed macro-
scopically under a stereoscope employing dark ﬁeld illumination to
visualize the coating.
2.6. Porcine coronary artery implants
Porcine coronary artery implants and subsequent SEM, histopathol-
ogy and histomorphometry analyses were performed at CBSET, Inc.
(Lexington, MA) using laboratory standard operating procedures.
For histopathology andhistomorphometry, Yucatanmini-swinewere
implanted with AC-SES and/or Vision® bare metal stents (BMS, Abbott
Vascular, Santa Clara, CA) for 3, 30 or 90 days. Stents were deployed in
porcine coronary arteries at a balloon:artery ratio of approximately
1.13:1 in either a single stent conﬁguration or in an overlapping stent
conﬁguration using same-stent pairs (AC-SES or BMS) overlapped by ap-
proximately 50%. Eight single stents or stent pairs were used for each
stent type and time point.
For pharmacokinetic analysis, Yucatan mini-swine were implanted
with AC-SES for 1, 3, 7, 14, 21, 30, 45, 60, 90 and 180 days (a minimum
of six stents per time point). One AC-SES was deployed in one porcine
coronary artery per pig at a balloon:artery ratio of approximately
1.15:1.
2.7. Histology and morphometry
At the termination of the in-life portion of the study, porcine hearts
were perfusionﬁxed at 100 mmHg. Fixed, stented vesselswere dissected
from themyocardium, sectioned and stainedwith hematoxylin and eosin
as well as Verhoeff's tissue elastin stain. Light microscopy was used to
score the tissue for histopathological variables as described in Supple-
mental Materials. Scoring was performed by a pathologist (co-author
J.R.L.S.) in a blinded fashion. Inﬂammation and injury were scored on a
per strut basis and the average was calculated per plane and per stent.
Quantitative morphometric analysis was performed on the histo-
logical sections from each stented artery using standard light micros-
copy and computer-assisted image measurement systems (Olympus
MicroSuite Biological Suite). Lumen area, IEL bounded area, stent
area and EEL bounded area were all measured directly. From these
measurements, all other morphometric parameters were calculated.
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Hearts were removed and the stented vessels were dissected from
the myocardium including vessel proximal and distal to the stented
segment. The stent was cut longitudinally and tissue was removed
from the stent. Drug content was assessed separately from the stent
and the tissue surrounding the stent. During manual separation of
the stent from the arterial tissue, tissue embedded coating deposits
were retained with the tissue fraction and account for additive drug
in the measured tissue concentrations seen during analysis of drug
content. Blood levels were also measured from a separate set of pigs
and include additional time points minutes to hours after implanta-
tion. Concentration of drug in tissue, blood and on stents was deter-
mined using a validated HPLC-MS/MS method using an Agilent
1200 LC system paired to Applied Biosystems API5500 MS with Ana-
lyst 1.5 software.
2.9. Data acquisition and analysis
Data are presented as mean±standard error. For selected contin-
uous data, if the assumptions of normality and homogeneity of vari-
ance were met, treatment differences were assessed by group t-test.
If normality or homogeneity of variance were not met, treatment dif-
ferences were assessed by Mann–Whitney Rank Sum test. For multi-
ple comparisons, treatment differences were assessed by a Kruskal–
Wallis One Way Analysis of Variance on Ranks. For all statistical
tests, the null hypothesis of no difference was only rejected if the
value of the calculated statistic was less than 0.05 (pb0.05).
2.10. Computational studies
We developed a 2D computational pharmacokinetics model to eval-
uate the inﬂuence of coating deployment on drug distribution patterns
relative to a representative pair of rectangular struts (Fig. 1). Strut
dimensions (60×80 μm) and inter-strut separation (1.35 mm) were
based on AC-SES dimensions and the initial polymer coating idealized
as 5-μm thick conformal layer. Motivated bymorphometrymicrographs
(Fig. 5), coating deployment was modeled as a vertical and horizontal
migration of coating segments. Drug elution was implemented as a pre-
scribed constantﬂux at the interfaces between coating and tissue (basedFig. 1. Scaled schematic representation of the 2D computational domain of a tissue em-
bedded strut pair apposed to the internal elastic lamina (IEL). Depicted here is the
baseline case of conformable strut-adherent coating.Notations: t - time since stent implan-
tation; n - unit normal; c - concentration of free drug, bNS and bREC - concentrations of, re-
spectively, non speciﬁc - (NS) and receptor - (REC) bound drug; bNS,max and bREC,max -
concentrations of NS binding sites and receptors; konNS and konREC- respective binding
on-rate constants, KdNS and KdREC - respective equilibrium dissociation constants; D ‐ drug
diffusion coefﬁcient in arterial tissue (for parameter values see Table S2, Supplemental
Materials).on early in vivo release kinetics). Drug transport in the tissue was as-
sumed to be governed by a constant isotropic diffusion coefﬁcient and
bimolecular binding [13] to nonspeciﬁc tissue sites and to intracellular
FKBP12 [14], using published parameter estimates (Table S1, online
supplement). Luminal and periadventitial washout were accounted for
by applying perfect sink boundary conditions at these interfaces [9,15].
In accordance with the periodicity of the stent geometry, proximal
(inlet) and distal (outlet) boundaries of the computational geometry
were treated as perfect insulators (e.g. symmetry boundary conditions).
Model equationswere solved numerically using the commercial ﬁnite
element package COMSOL 3.5a. Computational domains corresponding
to a range of coating migration scenarios were meshed using 12,000–
20,000 triangular Lagrange quadratic elements (90,000–170,000 degrees
of freedom). The resulting system of algebraic equations were solved
with a direct linear solver and integrated using a ﬁfth order backward
differencing scheme with variable time stepping and tight tolerances
(relative tolerance of 10−10 and absolute tolerance of 10−12). A prelimi-
nary mesh reﬁnement study conﬁrmed mesh independence of the nu-
merical solution for the utilized mesh density.
While modeling provides important insights into the kinetics of
drug dissociating from the stent it does not directly quantify how
much of the drug released is free relative to that still embedded in
coating deposits.
3. Results
3.1. Stent coating and stability
The electrostatic coatingprocess results in thedeposition of dry pow-
der, crystalline sirolimus onto the stent surface. This is a solvent-free
coating process further differentiated by the use of supercritical ﬂuid
technology to apply the polymer component [16]. The average crystal
particle size of the drug deposited on the stent surface is 2.7 μm with
all particles between 1.0 and 10 μm.
Because the drug is never dissolved in solvent the crystal structure
is maintained during application of the coating. Drug and polymer are
layered onto the stent and each layer is sintered to fuse the coating
into a smooth, conformal, well-adhered ﬁlm (Fig. 2).
Maintaining the crystalline structure of sirolimus within the coating
conferred enhanced drug stability. When coated stents were incubated
in serum-supplemented cell culture medium at 37 °C, a reduced per-
centage of degradants relative to parent drug were found in the stent
coatings containing crystalline sirolimus compared to a standard stent
coating containing approximately the same amount of sirolimus but
in amorphous form. The levels of the major sirolimus degradant two
weeks after incubation under simulated use conditions rose from a
baseline value of 0.1%±0.06% to 11.0%±1.0% in stents coated withFig. 2. Sequential addition of PLGA and micronized sirolimus is followed by sintering
that fuses the layers into a smooth, conformal stent coating.
Fig. 3. AC-SES stents were incubated in a ﬂow loop for up to 14 days and imaged
through the clear silastic tubing with dark ﬁeld microscopy. Coating spread is seen as
a broadening of the white areas surrounding the stent struts. Bars represent 500 μm.
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sirolimus the increase in degradant was much reduced. Here the rela-
tive amount of degradant increased from 0.5%±0.5% to 3.2%±1.8%).
This 3.4 fold lower value of relative degradant after two weeks of incu-
bation represents a statistically signiﬁcant reduction in sirolimus degra-
dation (pb0.05).
3.2. Coating dispersion and drug delivery
Absorbable coatings behave differently compared to strut-adherent
durable polymer coatings. The structure of the absorbable coating enables
the polymermaterial to soften and spread after implantation. Fig. 3 shows
results from ﬂow loop studies performed to visualize coating changes in
the AC-SES under simulated implant conditions employing pulsatile
ﬂow. In this study, changes in coating morphology were evaluated up
to 14 days and the coatingwas found to become swollen and to gradually
spread away from the stent strut in a uniform manner. No evidence of
delamination was found to occur.
The ﬂow loop studies involved a simpliﬁed, cell-free preparation
where serial visualization of changes in coating morphology is possi-
ble. In the ﬂow loop studies, the stent is deployed against the wall of a
ﬂexible polymer tube and ﬂuid is pumped through the tubing to hy-
drate the coating. These studies differ from in vivo implantation into
a coronary artery, because in the in vivo situation the stent coating
is in direct contact with tissue. As the coating degrades and becomes
more porous, cells within the neointima can intercalate into the coating
and cause the coating to separate from the stent struts. Most polymer
materials, including PLGA, are labile and susceptible to dissolution in
the ﬂuids used for histological processing of stented tissue sections.
The location, size and shape of the polymer coating in histology sections
is witnessed rather as the “negative image” of a space occupying mass.
Fig. 4 illustrates this phenomenon and provides evidence of coatingFig. 4. Data from preclinical studies evaluating AC-SES after 30 day implant in the por-
cine coronary implant model. The square-shaped clear spaces represent the stent strut
(S) location though the actual strut was lost during processing of the histology slides.
In each panel, distinct, irregularly shaped clear spaces (B, D: black arrows) represent
areas previously occupied by coating that has been lost during processing. Coating
can be seen to have spread into the surrounding neointima either close to the strut
(A, B) or relatively distant (C, D). Bars represent 200 μm (A, C) and 75 μm (B, D).spread or deposition in the intima 30 days after AC-SES implantation
into porcine coronary arteries.
The spreadable coating reduces the load of drug immediately around
the stent strut and extends polymer/drug coating from the strut. The
coating deposits contain drug still locked in a crystalline lattice com-
bined with the softened PLGA polymer. Thus, the area of drug delivery
is increased beyond the immediate vicinity of the stent strut. Modeling
of this phenomenon demonstrates that at small migration distances de-
position is enhanced due to greater surface area of elution. Above some
threshold distance, deposition is also enhanced by saturation of binding
sites that are otherwise free in the strut-adherent case (Fig. 5).
3.3. Rapid coating absorption
By 90 days after implantation there is no further evidence of coat-
ing deposits suggesting near complete absorption of coating by that
point (Fig. 6). Following implantation of any stent coated with an ab-
sorbable polymer, the thickness of the strut and its associated coating
will vary over time as the polymer absorbs. After 90 days, the absence
of stent coating leaves the struts (represented as “S” and seen as the
square shaped clear space) at their bare metal dimensions.
3.4. Controlled and consistent drug release
When drug is locked in a crystalline latticewithin the stent coating it
must dissociate from the crystal before diffusion through the polymer
and elution from the coating can commence. When drug solubilization
is rate-limiting, the rate of drug elution will remain relatively constant
over time exhibiting release kinetics that are far less concentration
gradient-dependent than classic diffusion-based drug delivery systems.
Published theoretical analyses [17] predict that dissolution controlled
release of crystalline drugs should display zero order kinetics elution
after a negligibly small initial burst. Indeed the AC-SES displays a virtual
absence of an initial burst of drug release (Fig. 7). The stent containing
crystalline sirolimus releases its drug in a near linear fashion over sever-
al weeks. Within 45–60 days the stent is essentially free of sirolimus
(less than 3% remains at the 45 day time point).
3.5. Drug transfer to tissue
In vivo release of drug from the stent is complete within 45–
60 days after implantation into porcine coronary arteries (Fig. 7,
open circles). The average release rate amounts to ~3 μg/day of
sirolimus from a 3.0×15 mm stent. Control over sirolimus release
results in efﬁcient drug transfer to and deposition within the arterial
tissue (Fig. 7, closed circles).
Early after implant the coating is still ﬁrmly attached to the stent
as demonstrated in the ﬂow loop studies. During this time, the vast
majority of drug remains in the coating adhered to the stent. Some
drug is seen in tissue and likely consists largely of free drug released
from the coating. As time goes on, drug still trapped in coating that
has dissociated from the stent (Fig. 4) will represent an increasing
fraction of the measured amount of drug in tissue. We hypothesize
that by day 30 polymer degradation progresses to the point where
coating adhesion begins to appreciably decline so that a much greater
percentage of coating can detach from the stent and disperse into tis-
sue where it is quantiﬁed as “arterial drug concentration.” Between
45–60 days, all the coating is released from the stent. From that
point on, the tissue levels will fall as drug is slowly cleared from the
site and there is no residual sirolimus left on the stent to supply addi-
tional drug.
3.6. Biocompatibility throughout the period of polymer absorption
Despite the sustained presence of sirolimus after implantation of
the AC-SES in porcine coronary arteries, endothelialization was not
Fig. 5. Modeling of drug delivery characteristics based on the assumptions that the
coating moves lateral relative to the stent strut, that both struts have the same amount
of coating migration and that (in this example) approximately 30% of the coating mi-
grates. All color schemes are uniform (0–1 for bound receptors; 0–40 ng/mg for depos-
ited drug). “Conformal” refers to strut-adherent coating and the numbers 35, 100 and
350 represent relative distances from the stent strut.
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plantation (Table 1).
Implantation of this unique stent system coated with crystalline
sirolimus and PLGA into porcine coronary arteries generated a benign
tissue response characterized by the expected increase in ﬁbrin depo-
sition and some minimal mineralization (Figs. 4 and 6). The porcine
coronary artery implant model used was a safety model involving
minimal overstretch. This non-overstretch model typically shows lit-
tle neointimal hyperplasia except in the presence of additional stim-
uli such as pro-inﬂammatory stent coatings. Following single stent
placement in this model, the AC‐SES resulted in a tissue response sim-
ilar to that seen following placement of the control BMS. When this
model is challenged, however, with placement of two overlapping
stents, then even bare metal stent implantation will trigger an in-
creased tissue response [18,19]. Implantation of overlapping AC‐SES
resulted in reduced inﬂammation and neointimal hyperplasia com-
pared to implantation of overlapping bare metal control stents at 30
and 90 days after implantation (Figs. 8 and 9, Table 1).Fig. 6. After 90 days of implantation, the coating is largely absorbed as is evidenced by
the resolution of clear areas representing space-occupying coating. Bars represent
100 μm.4. Discussion
The principal advantage of an absorbable stent coating has been
viewed as its temporary residence time such that any inﬂammatory
potential brought about by its presence is of limited duration. We
show here that additional beneﬁt can be derived from the ability of
the absorbable coating to soften, spread and migrate into surrounding
tissue. This deployment of the coating provides more uniform drug
distribution and the ability to saturate binding sites farther from the
stent struts. Drug therapy is mediated by this binding to target recep-
tors and it is the amount of drug bound to these receptors at any
given time that dictates drug effectiveness, not the total amount of
drug present either on the stent or in the artery. As vessel injury
from balloon delivery of the stent occurs all along the vessel wall,
anti-restenotic therapy is optimized by receptor binding both at and
between stent struts. Equally important to the expanded area of
drug delivery is the consequent reduction in peak drug concentra-
tions in the immediate vicinity of the stent struts. High concentra-
tions of drug may result in focal regions of tissue toxicity and vessel
thrombogenicity [20].
The crystalline nature of the drug load in the AC-SES coating pro-
vides additional control over drug delivery. The drug locked in crys-
talline particles does not diffuse within the coating and after
implantation of the AC-SES far less drug is available for immediate re-
lease. This eliminates the burst of drug release seen otherwise with
most commercially available strut-adherent matrix DES products.
The burst seen with other products within minutes to hours after
stent implantation is equivalent to delivery of a large bolus of drug
that is more than the artery can retain [21] and much of the excess
drug is washed away in the systemic circulation. In contrast, systemic
sirolimus levels in the porcine coronary implant model following im-
plantation of the AC-SES containing crystalline sirolimus remain
below the level of quantiﬁcation (b0.1 ng/ml) at all times [22]. Re-
lease of a large burst of drug soon after stent implantation at a time
when there is little or no neointima separating the stent from the en-
dothelium may cause additional endothelial damage and dysfunction
[23].
Drug that is part of a crystalline structure must overcome a high
activation energy barrier to dissociate from that crystal before it can dif-
fuse away from the coating. Thismeans that the dissociation/dissolution
reaction becomes the rate-limiting step in drug delivery rather than the
diffusion of drug from the stent [24]. With dissociation from the crystal-
line lattice controlling the rate of drug release, a more consistent rate ofFig. 7. Drug release was shown to be complete within 45–60 days after stent implanta-
tion into porcine coronary arteries. The average daily release rate amounts to approx-
imately 3 μg of sirolimus from a 3.0×15 mm stent. Arterial levels of drug were
quantiﬁed from arterial tissue surrounding the stented segment. Each data point repre-
sents the average from quantiﬁcation of six stents. Data are presented as ± standard
error.
Fig. 8. Comparison of AC-SES with BMS at 30 and 90 days after implant under condi-
tions of single or overlapping (OLP) stent conﬁgurations. Inﬂammation was scored as
described in Table 1. Neointimal thickness was calculated by subtracting the lumen di-
ameter from the internal elastic lamina diameter and dividing by two. Data are
presented as ± standard error. * pb0.05.
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remaining in the coating.
The slow, consistent release of drug from the AC-SES sustains drug
release for an extended period. This allows for delivery of drug throughout
theperiodof polymer absorption. As sirolimus is both ananti-inﬂammatory
agent [25,26] aswell as an anti-proliferative drug, its presence can counter-
act any tissue reaction from generation of polymer degradation products
during the period of polymer absorption. Ideally, sirolimus should be deliv-
ered from the DES at a consistently therapeutic dose that is sufﬁcient to
limit intimal hyperplasia without delaying the re-endothelialization of the
vessel critical to healing. The AC-SES appears to accomplish this goal as
endothelialization after implantation was not different from that of a
BMS. By balancing drug delivery with the relatively rapid absorption of
the polymer within a 90-day period the AC-SES optimizes therapy and al-
lows for healing without concerns of late vascular events due to lingering
effects of stent coating.
The use of this rapidly absorbable PLGA formulation adds a new di-
mension to coated stents, the potential for a deployable coating. The
time-dependent changes in PLGA stent-coatingmorphology and integri-
ty have recently been described [27] based on in vitro and in vivoTable 1
Comparison of AC-SES and BMS at 30 days in porcine coronary arteries.
Parameter AC-SES BMS
Endothelialization Complete Complete
Neointimal area 1.38 mm±0.44 mm* 2.26 mm±0.82 mm
Area % stenosis 22%±9% * 35%±12%
Neointimal thickness 0.17 mm±0.07 mm* 0.28 mm±0.11 mm
* pb0.05.degradation studies analyzed by a variety of techniques including light
microscopy, gel permeation chromatography, weight loss, ﬁeld-
emission environmental scanning electron microscopy (SEM) and stan-
dard SEM. After implantation, any bioabsorbable polymer absorbs mois-
ture from the surrounding tissue and begins to swell. Hydration leads
eventually to polymer degradation by the process of hydrolytic cleavage
of the ester bonds. Polymermolecular weight decreases relatively rapid-
ly as bonds are broken,mass loss occursmore slowly. These data demon-
strate a homogenous degradation process in which the coating
maintains its integrity and strong adhesion to the strut during the entire
degradation process. Implantation of the AC-SES in a ﬂow loop resulted
in a similar ﬁnding of PLGA swelling and spread.
In these studies no delamination was observed; however it is im-
portant to note that the in vivo degradation studies performed by Xi
et al. utilized a PMMA chamber to exclude cells from making contact
with the coated stent after subcutaneous implantation. Direct contact
with cells such as occurs after coronary artery implantation will lead
eventually to cell inﬁltration into the degrading coating and this will
serve to separate the coating from the stent struts. Similar to the ben-
eﬁt derived from a more uniform tissue distribution of sirolimus,
spreading of polymer in the tissue may facilitate absorption and di-
lute the local accumulation of degradation products.
Coating dispersion will only be useful from a drug delivery per-
spective if the time course of morphological changes is matched by
the time course of drug delivery. Other known stents coated with ab-
sorbable polymers have a relatively prolonged degradation such that
movement of the polymer is likely to occur only after several months
[28]. At the same time, as described above, the drug within these
coatings is in an amorphous form that is released from the stent rela-
tively quickly, often losing much of the drug load in a burst within mi-
nutes to hours after implantation. In these cases, by the time the
polymer coating disperses into the tissue, there is no longer sufﬁcient
drug remaining in the coating to provide enhanced drug delivery.
In conclusion several aspects of the AC-SES lend themselves to im-
proved drug delivery. The inclusion of crystalline rather than amor-
phous drug in the coating results in consistent drug release kinetics
that lack an initial burst. A deployable polymer coating reduces the vi-
cissitudes in drug levels and broadens that area of arterial wall with
binding site occupancy. The polymer coating absorbs rapidly leaving a
bare metal stent with fewer concerns about long-term biocompatibility.Fig. 9. Day 30 AC-SES (A) Vision BMS (B) overlapping stents. Bars represent 1 mm.
567W.C. Carlyle et al. / Journal of Controlled Release 162 (2012) 561–567The resulting composite product reduces intimal hyperplasia compared to
a bare metal stent in a physiologically challenging setting of overlapping
stents.
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